These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9614337)

  • 1. New HPV E6 binding proteins: dangerous liaisons?
    Kubbutat MH; Vousden KH
    Trends Microbiol; 1998 May; 6(5):173-5. PubMed ID: 9614337
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction of HPV E6 with p53 and associated proteins.
    Crook T; Vousden KH
    Biochem Soc Trans; 1994 Feb; 22(1):52-5. PubMed ID: 8206279
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif.
    Vande Pol SB; Brown MC; Turner CE
    Oncogene; 1998 Jan; 16(1):43-52. PubMed ID: 9467941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton.
    Tong X; Howley PM
    Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4412-7. PubMed ID: 9114003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a second transforming function in bovine papillomavirus type 1 E6 and the role of E6 interactions with paxillin, E6BP, and E6AP.
    Das K; Bohl J; Vande Pol SB
    J Virol; 2000 Jan; 74(2):812-6. PubMed ID: 10623743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive binding to a charged leucine motif represses transformation by a papillomavirus E6 oncoprotein.
    Bohl J; Das K; Dasgupta B; Vande Pol SB
    Virology; 2000 May; 271(1):163-70. PubMed ID: 10814581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of the interaction between HPV type 16 E6 and human E6-associated protein.
    Daniels PR; Sanders CM; Coulson P; Maitland NJ
    FEBS Lett; 1997 Oct; 416(1):6-10. PubMed ID: 9369221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
    Crook T; Tidy JA; Vousden KH
    Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
    Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
    Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.
    Kiyono T; Hiraiwa A; Fujita M; Hayashi Y; Akiyama T; Ishibashi M
    Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11612-6. PubMed ID: 9326658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes.
    Vousden K
    FASEB J; 1993 Jul; 7(10):872-9. PubMed ID: 8393818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    Scheffner M; Werness BA; Huibregtse JM; Levine AJ; Howley PM
    Cell; 1990 Dec; 63(6):1129-36. PubMed ID: 2175676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
    Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
    Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6.
    Gardiol D; Banks L
    J Gen Virol; 1998 Aug; 79 ( Pt 8)():1963-70. PubMed ID: 9714244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoexpression of mutant p53 and human papillomavirus related E6 oncoprotein in anal malignancies.
    Gupta S; Sharma BK
    Indian J Exp Biol; 1998 Sep; 36(9):875-8. PubMed ID: 9854426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
    Thomas M; Pim D; Banks L
    Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes.
    Watson RA; Thomas M; Banks L; Roberts S
    J Cell Sci; 2003 Dec; 116(Pt 24):4925-34. PubMed ID: 14625386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53-Dependent and -independent transactivation by the E6 protein of human papillomavirus type 16.
    Akutsu N; Shirasawa H; Asano T; Isono K; Simizu B
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():459-63. PubMed ID: 8601782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.